Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Plasma cell 1 Gastrointestinal 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 178 Bortezomib 100 Lenalidomide 90 daratumumab 47 Melphalan 46 Thalidomide 44 pomalidomide 43 Cyclophosphamide 38 Calcium Dobesilate 30 carfilzomib 29 Prednisone 19 Doxorubicin 16 elotuzumab 14 Filgrastim 14 isatuximab 12 ixazomib 11 Granulocyte Colony-Stimulating Factor 11 Vincristine 10 Peripheral Blood Stem Cell Transplantation 10 dexamethasone acetate 9 belantamab mafodotin 9 Zoledronic Acid 8 selinexor 7 Epoetin Alfa 7 fludarabine 6 Etoposide 6 dexamethasone 21-phosphate 5 auricularum 5 Mycophenolic Acid 5 Cisplatin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × tanespimycin × Plasma cell × Clear all

NCT00546780 2011-06-28

BMS TIME-1

Bristol-Myers Squibb

Phase 3 Completed

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡